How Pharmaceutical Companies Delay Generic Drug Access in Europe
March 28, 2025 · Frisian News
European pharmaceutical giants use legal tactics and patent strategies to block cheaper generic versions of drugs from reaching patients. Health authorities struggle to enforce timely access as companies exploit loopholes in European regulations.
Last week, Italian regulators blocked a generic version of a common heart drug because the original patent holder filed a last-minute complaint about labeling. The drug works identically to the brand name version. It costs half the price. Yet patients in Italy will wait another six months for access, and the pharmaceutical company gets six more months of monopoly sales. This scene repeats across Europe every week.
Pharmaceutical firms deploy a strategy called 'evergreening' to keep generics off shelves. They make small changes to drug formulations, apply new patents, extend exclusivity periods, or file legal challenges to generic approvals just before they take effect. European patent law gives these companies multiple opportunities to obstruct. Patent offices in Brussels, Amsterdam, and other capitals process hundreds of these blocking actions annually. Few national governments have the resources to fight them quickly.
The cost falls on patients and taxpayers. Generic drugs cost 80 to 90 percent less than originals. When companies delay generics by two or three years, European health systems spend billions in unnecessary expenses. Germany alone loses roughly 2 billion euros yearly to delayed generic entry. Smaller countries face even sharper budget pressures. Hospitals ration treatments, cut staff, or defer equipment purchases because generic prices never arrive as fast as they should.
European Union regulators know this happens. The European Medicines Agency and national health authorities have flagged the problem in reports dating back a decade. Yet Brussels has refused to tighten timelines or impose penalties for frivolous patent claims. Pharmaceutical lobbies influence policy. These companies employ hundreds of lawyers and spend millions on political access. Small patient groups and generic manufacturers lack the same firepower. The system works exactly as the strongest side designed it.
Generic manufacturers and health advocates push for faster review processes and penalties for abuse. Some nations have tested accelerated approval paths with modest success. The real fix requires political will: governments must decide whether they serve patients or corporations. So far, across Europe, the answer remains unclear.
Fuolke wike blokkearren Italjenske regeljevers in generike ferzje fan in faak brûkt herthartmedisyn om't de orizjinale patenthouer in lêste minút klacht yntsjinne oer de etiketearring. It medisyn wurket identyk oan de merkferzje. It kostet heal sa folle. Mar pasjinten yn Itallije moatte noch seis moannen wachtsje, en it farmasetytske bedriuw krijt seis moannen ekstra monopoly-ynkoamsten. Dit toniel herhellet har elke wike yn Europa.
Farmaseten brûke in strategie neamd 'evergreening' om generike middelen út winkels te hâlden. Se bringje lytse feroaringaon yn medisyn-formules, diene nije patenten yn, ferlinge eksklusiviteitperioden, of diene juridyske tsjinberjochten yn tsjin generike goedferklaaring krekt foar't dizze fan krêft wurde. Europesk patintrecht jouwt dizze bedriuwen meardere mooglikhedon om te obstruearjen. Patintburos yn Brussel, Amsterdam en oare stêd ferwurkje jaarlikse hûnderts fan dizze blokkearaksjes. Wai pear nasjonale regeerringen hawwe de middelen om gau tsjin terjochtsje.
De kosten falle op pasjinten en belasting-betalers. Generike medisinen koste 80 oant 90 persint minder as originelen. Wannear bedriuwen generike medisinen twa of trije jier fertrage, jive Europeske sûnensystemen miljarden út oan ûnnodige útjiften. Dûtskland allinnich ferliest roulik 2 miljard euro per jier troch fertrage generike ynankomst. Lytse lannen helje noch skerper budjetdruk. Sikehûzen rasjonearje behanneling, sniede personiel wei, of stelle útriisting-oankeap út om't generike prizen nea sa gau as se kinne komme.
Europeske Uny regeljevers witte dat dit bart. It Europesk Medisyn Bureau en nasjonale sûnensautoriteiten hawwe it probleem oanhâlden yn rappoarten út mear as tsien jier tebek. Dochs hat Brussel wegere termijnen skerp te meitsjen of straffen foar dwaze patintclaims yn te stellen. Farmasetytske lobbys befloedzje belied. Dizze bedriuwen wurkje hûnderts advokaten en jive miljoen út op politike tagong. Lytse pasjintgroepen en generike fabrikanten hawwe de selde fuerkrêft net. It systeem wurket presys sa't de sterkste partij it ûntworpen hat.
Generike fabrikanten en sûnensfoarstandders driunge oan op flugger beoardelings-prosedyres en straffen foar misbrûk. Oare lannen hawwe flugge goedferklaaring-paden mei middelmatige sukses test. De echte oplossing freget politike wol. Regeerringen moatte beslisse oft se pasjinten of bedriuwen tsjinje. Oant no ta bliuwt it antwurd yn Europa ûnklier.
Published March 28, 2025 · Frisian News · Ljouwert, Fryslân